TOP TEN perturbations for 39623_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39623_at
Selected probe(set): 206022_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39623_at (206022_at) across 6674 perturbations tested by GENEVESTIGATOR:
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):8.330738Number of Samples:2 / 4
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary clear cell adenocarcinoma (NOS) of the ovary. |
expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-7.9736633Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous surface papillary carcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Relative Expression (log2-ratio):7.9715176Number of Samples:2 / 5
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (carcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary. |
expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-7.709545Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-7.498762Number of Samples:51 / 2
| Experimental | expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):-7.4674397Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):7.465102Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):7.3878317Number of Samples:2 / 7
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary adenocarcinoma (NOS) of the ovary. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):6.6877193Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
monocyte activation study 1 (NOD2L/TLR/1L; 6h) / untreated monocyte sample (6h)
Relative Expression (log2-ratio):6.5252924Number of Samples:5 / 5
| Experimental | monocyte activation study 1 (NOD2L/TLR/1L; 6h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1). | |
| Control | untreated monocyte sample (6h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 6 hours for RNA isolation. |